Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2012
08/07/2012US8236507 Modulators of TNF receptor associated factor (TRAF), their preparation and use
08/07/2012US8236351 Tamper-resistant oral opioid agonist formulations
08/07/2012US8236340 Drug formulations for coating medical devices
08/07/2012US8236335 Antimicrobial nanoemulsion compositions and methods
08/07/2012US8236311 Antibodies against clostridium difficile toxins and uses thereof
08/07/2012US8236048 Drug/drug delivery systems for the prevention and treatment of vascular disease
08/07/2012CA2559755C Dietary supplement and method for treating digestive system-related disorders
08/07/2012CA2553827C New combinations of an anti emetic agent and an enkephalinase inhibitor
08/07/2012CA2477737C Multi-substituted selective androgen receptor modulators and methods of use thereof
08/07/2012CA2450087C Benzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use
08/07/2012CA2447367C Diagnosis and treatment of malignant neoplasms
08/07/2012CA2445421C Von willebrand factor (vwf)-cleaving protease
08/07/2012CA2429216C Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors
08/07/2012CA2420226C Methods for treating demyelinating diseases
08/07/2012CA2317721C Novel steroid-activated nuclear receptors and uses therefor
08/02/2012WO2012103186A2 Androgen composition for treating an opthalmic condition
08/02/2012WO2012102936A1 Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
08/02/2012WO2012102255A1 Indole derivative and pharmacologically acceptable salt of same
08/02/2012WO2012102254A1 Indole derivative, and pharmacologically acceptable salt thereof
08/02/2012WO2012101181A1 Compositions and methods for cell transplantation
08/02/2012WO2012078757A3 Combination for breast cancer therapy with hsp90 inhibitory compounds
08/02/2012WO2012071269A3 Selective removal of cells having accumulated agents
08/02/2012WO2011107653A8 Use of levodopa, carbidopa and entacapone for treating parkinson's disease
08/02/2012US20120196932 Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism
08/02/2012US20120196867 Composition comprising a pde4 inhibitor and a pde5 inhibitor
08/02/2012US20120196301 Use of binding partners for 5-ht5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders
08/02/2012US20120195965 Solid dosage form comprising a fibrate
08/02/2012US20120195934 Polymeric gel delivery system for pharmaceuticals
08/02/2012DE102011003478A1 Antivirales Mittel enthaltend rekombinante Mistellektine An antiviral agent containing recombinant mistletoe lectins
08/02/2012CA2825396A1 Androgen composition for treating an opthalmic condition
08/02/2012CA2825252A1 Compositions and methods for cell transplantation
08/02/2012CA2825172A1 Indole derivative and pharmacologically acceptable salt of same
08/02/2012CA2825134A1 Indole derivative, and pharmacologically acceptable salt thereof
08/02/2012CA2824766A1 Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
08/01/2012EP2481802A2 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
08/01/2012EP2481756A2 Compositions and methods for diagnosing and treating cancer
08/01/2012EP2481747A1 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
08/01/2012EP2481732A1 Condensed ring compound and use thereof
08/01/2012EP2481726A2 Crystal forms of saxagliptin and processes for preparing same
08/01/2012EP2481409A2 Nanoparticle comprising rapamycin and albumin as anticancer agent
08/01/2012EP2481408A2 New use of glutaminyl cyclase inhibitors
08/01/2012EP2481405A1 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
08/01/2012EP2481404A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
08/01/2012EP2481402A2 Nanoparticle comprising rapamycin and albumin as anticancer agent
08/01/2012EP2481399A1 Sustained drug delivery system
08/01/2012EP2480669A2 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
08/01/2012EP2480231A2 New benzathine salts of ace inhibitors, process for their preparation and their use for the treatment of cardiovascular diseases
08/01/2012EP2480227A1 Retinal neuroprotection by ion channel blockers regulated by the sur subunit
08/01/2012EP2480224A1 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
08/01/2012EP2480207A2 Micelle encapsulation of therapeutic agents
08/01/2012EP2480084A1 Combination
08/01/2012EP2149382B1 Dentinogenesis inducer and dentinogenesis pulp-capping material
08/01/2012EP1915994B1 Cyclic amine derivatives in combination with ppar regulators
08/01/2012EP1806152B1 Drug for external use and adhesive patch
08/01/2012EP1669080B1 Method of inhibiting alveolar resorption and peridental membrane loss and composition for internal use to be used therein
08/01/2012EP1303192B1 Dietary lipids for improving skin and coat of pets
08/01/2012EP1133310B1 Artery- and vein-specific proteins and uses therefor
08/01/2012EP0961612B2 Protein stabilized pharmacologically active agents and their use
08/01/2012CN102618542A MiRNA (microminiature ribonucleic acid) capable of regulating and controlling expression of HLA-G (human leukocyte antigen-G) and application of miRAN
08/01/2012CN102614515A Novel chemical restructuring high-density lipoprotein drug carrying system with targeted and double anti-tumor effects and application
08/01/2012CN102614514A GLP-1 acceptor agonists used for treating pains
08/01/2012CN102614176A Roflumilast for the treatment of pulmonary hypertension
07/2012
07/31/2012US8232401 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
07/31/2012US8232320 Antimicrobial nanoemulsion compositions and methods
07/31/2012US8232317 Method for increasing hair growth
07/31/2012US8232304 Antifungal formulations
07/31/2012US8232268 Carbapenem antibacterials with gram-negative activity and processes for their preparation
07/31/2012US8232259 Multiple CpG oligodeoxynucleotide and their use to induce an immune response
07/31/2012US8231910 Combining EDTA-sodium-metal complex(es) and the sodium selenite solution to from trace element soultuton to provide the solution to the animals
07/31/2012US8231905 Gastric retained gabapentin dosage form
07/31/2012US8231901 Opioid agonist formulations with releasable and sequestered antagonist
07/31/2012US8231885 Compounds, formulations, and methods for ameliorating telangiectasis
07/31/2012US8231874 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
07/31/2012US8231866 Cytokine protein family
07/31/2012CA2647158C Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
07/31/2012CA2506464C Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
07/31/2012CA2449999C Compounds and methods for the treatment or prevention of flavivirus infections
07/31/2012CA2404688C Nuclear factor .kappa.b inducing factor
07/31/2012CA2370948C Growth factor homolog zvegf4
07/31/2012CA2348624C Adenovirus-mediated gene therapy
07/31/2012CA2223402C Methods of inhibiting phagocytosis
07/26/2012WO2012099258A1 Therapeutic agent for alopecia
07/26/2012WO2012098090A1 Cb2 agonists for the treatment and prevention of endometriosis
07/26/2012WO2011107921A3 Modified release composition of milnacipran
07/26/2012US20120190909 Uses of il-12 in hematopoiesis
07/26/2012US20120190821 Recombinant soluble fc receptors
07/26/2012US20120190658 Method And Composition For The Treatment Of Adverse Skin Conditions
07/26/2012US20120190003 Organ arrest, protection, preservation and recovery
07/26/2012US20120189615 CROSS-ß STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS-ß STRUCTURE, FOR MODULATING CROSS-ß STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS-ß STRUCTURE-MEDIATED TOXICITY
07/26/2012US20120189602 Treatment and prevention of pulmonary conditions
07/26/2012US20120189576 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
07/26/2012US20120189556 Pharmaceutical compositions based on anticholinergics and corticosteroids
07/26/2012DE102011002934A1 CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose CB2 agonists for the treatment and prevention of endometriosis
07/26/2012CA2825382A1 Agent for the treatment of alopecia
07/25/2012EP2478918A2 Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
07/25/2012EP2478913A1 Synthetic HLA binding peptide analogues and uses thereof
07/25/2012EP2478907A2 Methods and compositions for treating cancer
07/25/2012EP2478902A1 Pharmaceutical composition for reducing weight and method for the production thereof
07/25/2012EP2478895A2 Compositions for treating esophageal disorders
07/25/2012EP2478894A2 Compositions for treating esophageal disorders
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 1151